Free Trial

Sagimet Biosciences (SGMT) Competitors

Sagimet Biosciences logo
$9.15 +0.47 (+5.41%)
Closing price 04:00 PM Eastern
Extended Trading
$8.95 -0.20 (-2.19%)
As of 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SGMT vs. COLL, AKBA, SYRE, MLYS, AVDL, PHVS, NRIX, ARDX, ORIC, and PRAX

Should you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Avadel Pharmaceuticals (AVDL), Pharvaris (PHVS), Nurix Therapeutics (NRIX), Ardelyx (ARDX), Oric Pharmaceuticals (ORIC), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

Sagimet Biosciences vs. Its Competitors

Collegium Pharmaceutical (NASDAQ:COLL) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Collegium Pharmaceutical has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 3.35, suggesting that its stock price is 235% more volatile than the S&P 500.

In the previous week, Collegium Pharmaceutical had 8 more articles in the media than Sagimet Biosciences. MarketBeat recorded 8 mentions for Collegium Pharmaceutical and 0 mentions for Sagimet Biosciences. Collegium Pharmaceutical's average media sentiment score of 0.88 beat Sagimet Biosciences' score of 0.51 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company Overall Sentiment
Collegium Pharmaceutical Positive
Sagimet Biosciences Positive

Collegium Pharmaceutical has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Collegium Pharmaceutical$631.45M1.61$69.19M$1.2225.88
Sagimet Biosciences$2M140.32-$45.57M-$1.76-5.20

Collegium Pharmaceutical has a net margin of 6.61% compared to Sagimet Biosciences' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 99.08% beat Sagimet Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Collegium Pharmaceutical6.61% 99.08% 15.14%
Sagimet Biosciences N/A -35.21%-34.09%

Collegium Pharmaceutical presently has a consensus target price of $43.75, indicating a potential upside of 38.58%. Sagimet Biosciences has a consensus target price of $26.60, indicating a potential upside of 190.71%. Given Sagimet Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Sagimet Biosciences is more favorable than Collegium Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Collegium Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Sagimet Biosciences
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

87.9% of Sagimet Biosciences shares are held by institutional investors. 2.5% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 14.7% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Collegium Pharmaceutical beats Sagimet Biosciences on 9 of the 16 factors compared between the two stocks.

Get Sagimet Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SGMT vs. The Competition

MetricSagimet BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$280.63M$2.88B$5.46B$8.92B
Dividend YieldN/A2.44%5.24%4.04%
P/E Ratio-5.2020.8027.0120.12
Price / Sales140.32193.35380.1493.35
Price / CashN/A41.7026.2128.59
Price / Book1.807.487.995.57
Net Income-$45.57M-$55.04M$3.16B$248.40M
7 Day Performance13.95%5.44%3.69%6.04%
1 Month Performance64.57%2.38%2.91%7.69%
1 Year Performance194.21%5.53%34.30%20.97%

Sagimet Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SGMT
Sagimet Biosciences
2.4052 of 5 stars
$9.15
+5.4%
$26.60
+190.7%
+193.2%$280.63M$2M-5.208
COLL
Collegium Pharmaceutical
4.1851 of 5 stars
$29.57
-1.2%
$43.75
+48.0%
-4.0%$961.71M$631.45M24.24210News Coverage
Analyst Downgrade
Buyback Announcement
AKBA
Akebia Therapeutics
4.2422 of 5 stars
$3.64
-0.3%
$6.75
+85.4%
+287.9%$958.62M$160.18M-17.33430
SYRE
Spyre Therapeutics
1.3425 of 5 stars
$14.97
-1.6%
$53.40
+256.7%
-40.0%$917.39M$890K-3.9773
MLYS
Mineralys Therapeutics
2.1521 of 5 stars
$13.53
-1.3%
$32.25
+138.4%
+8.8%$893.55MN/A-3.6328
AVDL
Avadel Pharmaceuticals
2.4593 of 5 stars
$8.85
-3.8%
$18.17
+105.3%
-39.9%$890M$169.12M-32.7870
PHVS
Pharvaris
1.7751 of 5 stars
$17.60
+3.5%
$36.20
+105.7%
+8.1%$888.93MN/A-5.8530Positive News
Gap Up
NRIX
Nurix Therapeutics
1.6045 of 5 stars
$11.39
-2.1%
$30.18
+164.9%
-36.5%$887.38M$54.55M-4.07300Upcoming Earnings
ARDX
Ardelyx
4.434 of 5 stars
$3.92
+6.2%
$10.89
+177.8%
-17.8%$882.85M$333.61M-17.8290
ORIC
Oric Pharmaceuticals
4.628 of 5 stars
$10.15
-1.6%
$19.17
+88.8%
+38.5%$878.66MN/A-5.4380Analyst Forecast
PRAX
Praxis Precision Medicines
2.9514 of 5 stars
$42.05
-2.2%
$109.90
+161.4%
+15.8%$875.87M$8.55M-3.92110Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:SGMT) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners